Completed PHASE1 INTERVENTIONAL 2-arm NCT01366560

Effect of GSK962040 on Oesophageal Function

A Double Blind Randomised Placebo Controlled Two Way Cross Over Study to Determine the Effect of GSK962040 on Oesophageal Function and Gastric Emptying in Healthy Male Volunteers.

Sponsor: GlaxoSmithKline

Conditions Gastrointestinal Motility

Interventions Active Placebo

Updated 7 times since 2017 Last updated: Jul 14, 2017 Started: Aug 31, 2010 Primary completion: Oct 22, 2010 Completion: Oct 22, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Gastrointestinal Motility and is currently completed. GlaxoSmithKline leads this study, which shows 7 recorded versions since 2010 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Aug 2017 — Jun 2018 [monthly]

Completed PHASE1

▶ Show 2 earlier versions

Jun 2017 — Aug 2017 [monthly]

Completed PHASE1
Jan 2017 — Jun 2017 [monthly]

Completed PHASE1

First recorded

Aug 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GlaxoSmithKline

Data source: GlaxoSmithKline

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Cambridge, United Kingdom